EP2262487A2 - An orally disintegrating tablet of cilostazol - Google Patents
An orally disintegrating tablet of cilostazolInfo
- Publication number
- EP2262487A2 EP2262487A2 EP09714454A EP09714454A EP2262487A2 EP 2262487 A2 EP2262487 A2 EP 2262487A2 EP 09714454 A EP09714454 A EP 09714454A EP 09714454 A EP09714454 A EP 09714454A EP 2262487 A2 EP2262487 A2 EP 2262487A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- orally disintegrating
- disintegrating tablet
- weight
- parts
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to an oral tablet comprising cilostazol which can be disintegrated in oral cavity.
- Cilostazol is 6- [4- (l-cyclohexyl-lH-tetrazol-5- yl)butoxy] -3, 4-dihydrocarbostyril as shown in the following formula (1), which exhibits high inhibitory action for platelet aggregation as well as inhibitory action for phosphodiesterase, antiulcer activity, hypotensive action, antiphlogistic action, etc. and thereby is widely used in clinical use as a drug for treating various ischemic symptoms caused by chronic arterial occlusion.
- cilostazol has been additionally approved as a medicament having an indication which prevents the relapse after treatment of cerebral infarction (except cardiogenic cerebral infarction) (JP-A-56 (1981) -49378) .
- the cilostazol tablets which are called Pletaal tablet 50 ® , Pletaal tablet 100 ® , Pletaal powder 20 % (OTSUKA PHARMACEUTICAL CO., LTD.) have already been on sale.
- the present inventors had extensively studied a variety of formulations of cilostazol preparations which are possible to be taken without water previously, and have found that a powder formulation thereof wherein mannitol is formulated could be an orally disintegrable formulation (WO 2007/001086) .
- a powder formulation or a particle formulation has some problems such as a difficult handling at the administration and an adhesion in oral cavity, and thus such formulation does not always satisfy elderly patients or patient suffering from swallowing disorder.
- JP-B-3841804, WO 2005/037254, and WO 2005/037319 disclose compositions comprising saccharide (s) , disintegrating agent (s) and inorganic excipient(s) in a certain proportion, which are suitable for the manufacture of orally disintegrable tablets.
- WO 2007/029376 discloses that such compositions can be improved by further adding lubricant (s) , disintegrating agent (s), and binder (s) to prepare more useful orally- disintegrable tablets.
- lubricant s
- disintegrating agent disintegrating agent
- binder binder
- each excipient contained in vehicle compositions of these orally disintegrable tablets had a widely broad range of choices and further the contents thereof were defined only by means of a certain range. It was unclear if a useful orally-disintegrable tablet of cilostazol could be prepared using the disclosed compositions, or if it was possible to select excipients suitable for an orally-disintegrable tablet of cilostazol from a widely broad range of excipients. Therefore, it was necessary for a skilled person to do extremely many experiments to find a useful orally-disintegrable tablet of cilostazol, and thus it was not thought that it was so easy to find a composition suitable for such tablet from the broad range.
- the present inventors have extensively studied in order to solve the above-mentioned problems, and have found that it is possible to prepare a useful orally- disintegrating tablet of cilostazol using the composition described in WO 2007/029376; and furthermore a specifically limited range selected from the range of the excipients and the content proportions thereof described in 2007/029376 makes it possible to prepare an orally disintegrating tablet of cilostazol having more useful advantages about the disintegrability in oral cavity, formulating property and manufacturing process. Based upon the new findings, the present invention has been completed.
- the present invention relates to the following inventions .
- the present invention provides an orally disintegrating tablet comprising cilostazol and granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, which exhibits a good disintegrability in the oral cavity and a pleasant feeling in a mouth when administered and also has a sufficient hardness.
- the present invention provides an orally disintegrating tablet comprising cilostazol, granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, and a glidant. Additionally, the present invention provides the orally disintegrating tablet which further comprises an organic excipient.
- the present invention provides an orally disintegrating tablet comprising cilostazol, granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, a glidant, and an organic excipient, which may further optionally comprise one or more kinds of additives selected from the group consisting of lubricants, sweeteners, flavoring substances, flavors, binders and colorants .
- the present invention provides an orally disintegrating tablet prepared by
- a preferable composition of the orally disintegrating agent comprises
- composition which is prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles of saccharides formed with mannitol and xylitol through a spray drying method, wherein
- the saccharides comprising the combination of mannitol and xylitol are contained in 40 - 90 parts by weight;
- the inorganic excipient is contained in 1 - 30 parts by weight;
- the disintegrating agent is contained in 5 - 40 parts by weight, provided that the total amount of ingredients (a) , (b) and (c) is contained in 100 parts by weight, and the ratio of mannitol and xylitol by weight is 98 : 2 - 67 : 33, and
- the starches are one or more kinds of starches selected from the group consisting of corn starch, rice starch, potato starch, partial pregelatinized starch, and hydroxypropyl starch;
- the celluloses are one or more kinds of celluloses selected from the group consisting of crystalline cellulose, and carboxymethylcellulose .
- the starches are corn starch, and the celluloses are crystalline cellulose.
- more preferable glidant is one or more selected from the group consisting of hydrous silicon dioxide, light anhydrous silicic acid, and heavy anhydrous silicic acid, and the most preferably, hydrous silicon dioxide, and/or light anhydrous silicic acid.
- the present invention provides an orally disintegrating tablet which is possible to be rapidly disintegrated in oral cavity, exhibits a pleasant feeling in a mouth when administered and also has a sufficient hardness, to many patients to whom cilostazol tablets are applied, especially aged patients and patients suffering from dysphagia.
- the present invention provides an orally disintegrating tablet of cilostazol, which is possible to be rapidly disintegrated in oral cavity, and exhibits a pleasant feeling in a mouth when administered and also an identical dissolution property with the commercial cilostazol tablet.
- the orally disintegrating tablet means a tablet prepared by adding particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, to cilostazol; especially, an orally disintegrating tablet prepared by adding to cilostazol, (i) particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides, (ii) a glidant and (iii) an organic excipient.
- Cilostazol can be prepared, for example, by the method described in JP-A-56 (1981) -49378.
- the "granulated particles which are prepared by uniformly dispersing an inorganic substance and a disintegrating agent into complex particles comprising two or more kinds of saccharides" (hereinafter referred to "granulated particles") used herein can be prepared by dispersing mannitol and a saccharide other than mannitol, a disintegrating agent, an inorganic substance in water and then spray-drying it.
- a composition for the orally disintegrating tablet which can be prepared by the method described in WO 2005/037254 or WO 2005/037319.
- the "two or more kinds of saccharides” contained in the granulated particles are a combination of mannitol and a saccharide which is not mannitol.
- the saccharide means a sugar or a sugar alcohol.
- the saccharide other than mannitol includes, for example, one or more selected from the group consisting of xylitol, sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, Palatinit ® , Palatinose ® and the like.
- the saccharide is a combination of mannitol and xylitol.
- the "inorganic substance" contained in the granulated particles is preferred to be a pharmaceutically acceptable inorganic acid compound comprising any one or more of aluminum, magnesium and calcium. It includes at least one ingredients selected from, for example, magnesium aluminometasilicate, magnesium aluminosilicate, calcium hydrogenphosphate, calcium hydrogenphosphate anhydride, calcium hydrogenphosphate anhydride granule, hydrotalcite, aluminum silicate, calcium phosphate, calcium carbonate, calcium silicate, magnesium silicate, magnesium oxide, magnesium hydroxide, alumina-magnesium hydroxide, dry aluminum hydroxide gel, magnesium carbonate, etc.
- the mean particle size of the inorganic substance is 0.1 - 100 urn, preferably 1 - 60 urn, and more preferably 1 - 40 urn. It is possible to use an inorganic substance milled by a conventional method in order to obtain the desired mean particle size.
- the "disintegrating agent" contained in the granulated particles is preferably at least one ingredients selected from crospovidone, croscarmellose sodium, low- substituted hydroxypropyl cellulose, and crystalline cellulose and, although any of them may be used as a single, it is preferred to use as a mixture of two or more thereof. Amongst them, it is more preferred to use crospovidone and crystalline cellulose. When using crospovidone and crystalline cellulose, the ratio by weight of crospovidone and crystalline cellulose is 5 : 8 - 15 : 22, preferably 5 : 10 - 14 : 22, and more preferably 6 : 12 - 13 : 21.
- the above disintegrating agent preferably has a mean particle size of 0.1 - 100 ⁇ m, more preferably 1 - 60 ⁇ m, and even more preferably 1 - 40 ⁇ m, in order to make a uniform dispersibility in the present composition and prevent a sandy feeling in oral cavity.
- the desired mean particle size can be obtained by using a disintegrating agent micronized via a conventional method.
- the saccharides are contained in 40 - 90 parts by weight, the inorganic substance is contained in 1 - 30 parts by weight, the disintegrating agent is contained in 5 - 40 parts by weight, and preferably the saccharides are contained in 50 - 80 parts by weight, the inorganic substance is contained in 2 - 15 parts by weight, the disintegrating agent is contained in 10 - 36 parts by weight.
- the saccharides are contained in 62 - 78 parts by weight, the inorganic substance is contained in 3 - 8 parts by weight, the disintegrating agent is contained in 18 - 34 parts by weight.
- the granulated particles can be prepared by a conventional method such as spray-drying method, fluid-bed granulation, agitation granulation and wet granulation (e.g. wet extrusion granulation), and also by the method described in WO 2007/029376. Such granulated particles are available, for example, as a commercially available F-MELT ® (FUJI CHEMICAL INDUSTRY CO., LTD.) .
- the blending quantity of the granulated particles is generally about 10 - 60 % (w/w) , preferably about 20 - 40 % (w/w) per 100 % (w/w) of the orally disintegrating tablet.
- the "glidant" used herein includes hydrous silicon dioxide, light anhydrous silicic acid, heavy anhydrous silicic acid and the like; preferably, light anhydrous silicic acid, or hydrous silicon dioxide; and more preferably light anhydrous silicic acid.
- the glidant may comprise one or more of the above ingredients.
- the blending quantity of the glidant is about 0.2 - 2 (w/w), preferably about 0.5 - 1.5 % (w/w) per 100 % (w/w) of the orally disintegrating tablet.
- the "organic excipient" blended in the present solid formulation includes, for example, celluloses and starches.
- the celluloses include, for example, crystalline cellulose, carboxymethylcellulose, ethylcellulose, carboxymethylethyl cellulose, carmellose sodium, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and the like.
- it is crystalline cellulose or carboxymethylcellulose, and more preferably crystalline cellulose.
- the starches include corn starch, rice starch, potato starch, flour starch, partial pregelatinized starch, hydroxypropyl starch, and the like.
- the organic excipient may comprise one or more of the above ingredients.
- crystalline cellulose and corn starch are used.
- the blending quantity of the organic excipient is about 5 - 60 % (w/w) , preferably about 10 - 30 % (w/w) per 100 % (w/w) of the orally disintegrating tablet.
- the present invention can include a variety of additives which are generally used in the preparation of tablets as long as the additives do not negatively affect its disintegrability and formability.
- the additives include, for example, lubricants, sweeteners, flavoring substances, flavors, binders, and colorants.
- the lubricant includes, for example, stearic acid, metal stearate (e.g. magnesium stearate, and calcium stearate) , stearyl fumarate sodium, talc, colloidal silica, sucrose fatty acid ester, hydrogenated oil, and polyethylene glycol. Amongst them, stearic acid and metal stearate are preferable, and magnesium stearate is more preferable.
- the blending quantity of the lubricant is generally about 0.01 - 1 % (w/w) , preferably 0.1 - 0.6 %
- the sweetener includes, for example, acesulfame potassium, aspartame, saccharin or a salt thereof, glycyrrhizinic acid or a salt thereof, stevia or a salt thereof, sucralose, and thaumatin.
- the flavoring substance includes, for example, ascorbic acid or a salt thereof, glycine, sodium chloride, magnesium chloride, hydrochloric acid, diluted hydrochloric acid, citric acid or a salt thereof, anhydrous citric acid, L-glutamic acid or a salt thereof, succinic acid or a salt thereof, acetic acid, tartaric acid or a salt thereof, sodium hydrogen carbonate, fumaric acid or a salt thereof, malic acid or a salt thereof, glacial acetic acid, disodium inosinate, and honey.
- ascorbic acid or a salt thereof glycine, sodium chloride, magnesium chloride, hydrochloric acid, diluted hydrochloric acid, citric acid or a salt thereof, anhydrous citric acid, L-glutamic acid or a salt thereof, succinic acid or a salt thereof, acetic acid, tartaric acid or a salt thereof, sodium hydrogen carbonate, fumaric acid or a salt thereof, malic acid or a salt
- the flavor includes a favoring agent, for example, orange essence , orange oil, caramel, camphor, cinnamon oil, spearmint oil, strawberry essence, chocolate essence, cherry flavor, spruce oil, pine oil, mint oil, vanilla flavor, bitter essence, fruit flavor, peppermint essence, mixed flavor, mint flavor, menthol, lemon powder, lemon oil, and rose oil.
- a favoring agent for example, orange essence , orange oil, caramel, camphor, cinnamon oil, spearmint oil, strawberry essence, chocolate essence, cherry flavor, spruce oil, pine oil, mint oil, vanilla flavor, bitter essence, fruit flavor, peppermint essence, mixed flavor, mint flavor, menthol, lemon powder, lemon oil, and rose oil.
- the binder includes, for example, gum arabic, powdered acacia, gelatin, agar, dextrin, pullulan, povidone, and polyvinyl alcohol.
- the colorant includes, for example, food colorant such as food dye Red No. 3, food dye Yellow No. 5, and food dye blue No. 1; yellow ferric oxide, red ferric oxide, brown iron oxide, black iron oxide, copper chlorophyll, sodium copper chlorophyllin, riboflavin, powdered green tea.
- These additive ingredients can be generally used in any amount, and as a single or a mixture.
- the exemplified process of the present orally disintegrating tablet includes a method comprising (1) weighing cilostazol and the other materials for formulation, (2) mixing the ingredients in a mixer such as a V-blender to prepare a mixed powder for tablet, and (3) directly compressing the powder .
- a method of strongly mixing with an agitation granulation machine or a method of mixing and milling with a mill may be used.
- a compaction-granulation method with a dry granulator; a wet granulation method with water, acetone, ethyl alcohol, propyl alcohol or a mixture thereof wherein optionally a binder may be dispersed or dissolved; or a method of preparing the mixed powder for tablet via separating it into two or more groups may be used.
- a lubricant, a sweetener, a flavoring substance, a flavor, binder, a colorant, etc. may be optionally added thereto in preparing the mixed powder for tablet.
- cilostazol and a glidant it is preferable to sufficiently mix cilostazol and a glidant firstly, and then to add an organic excipient, granulated particles, a sweetener and a lubricant thereto and sufficiently mix the mixture again.
- the resulting mixed powder for tablet is compressed at a pressure of 200 kg - 600 kg/punch with for example a single tableting machine or a rotary tableting machine.
- the pressure is lower than the above- mentioned range, the tablet hardness can be shortened and thus does not arrive at a sufficient hardness to be handled. While, when the pressure is higher than the above-mentioned range, the disintegration of the tablet can be disadvantageously delayed.
- the compaction-formulation it is possible to use a conventional tableting method as well as an external lubricating compression.
- the external lubricating compression enables the amount of a lubricant to be decreased, the disintegration rate to be accelerated, and the tablet hardness to be enhanced.
- the shape of the orally disintegrating tablet it is possible to form any shape such as circular form, oval figure, globular shape, rod shape, and doughnut shape, as well as a lamination layer tablet, a dry-coated tablet, etc.
- the tablet may be coated by a conventional coating method used in the field of formulation.
- the orally disintegrating tablet can rapidly disintegrate in oral cavity with saliva, and hence it is possible to take a medicine smoothly.
- the hardness which is measured with a tablet hardness tester is 30 N or more.
- the disintegration time in oral cavity is generally within 90 seconds, preferably within 60 seconds, and more preferably within 40 seconds.
- any additives defined herein such as inorganic substance, disintegrating agent, saccharide, glidant, organic excipient, starch, cellulose, additive, lubricant, sweetener, flavoring substance, flavor, binder and colorant which are expressed as a single or a plural form may include one kind of ingredient, plural kinds of ingredients and a mixture of plural kinds of ingredients.
- cilostazol powder To 40 parts by weight of cilostazol powder were added 39.2 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 20 parts by weight of carmellose (NS-300, GOTOKU CHEMICAL COMPANY LTD.), 0.2 parts by weight of menthol (Takasago International
- cilostazol powder 39.2 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 10 parts by weight of crystalline cellulose (Ceolus PH-IOl, Asahi Kasei Chemicals Corporation) , 10 parts by weight of corn starch (Nisshoku corn starch (XXl 6) W, Nihon Shokuhin Kako Co., Ltd.), 0.2 parts by weight of menthol (Takasago International Corporation), 0.2 parts by weight of aspartame (AJINOMOTO CO., INC.) and 0.4 parts by weight of magnesium stearate
- cilostazol powder 39.2 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 20 parts by weight of rice starch (Micropearl, Shimada Chemical Company), 0.2 parts by weight of menthol (Takasago International Corporation), 0.2 parts by weight of aspartame (AJINOMOTO CO., INC.) and 0.4 parts by weight of magnesium stearate (TAIHEI CHEMICAL INDUSTRIAL CO. ,LTD.) .
- Example 4 After mixing, the mixture was compression-molded with a rotary tableting machine (HT- APl 8SSI I type, HATA IRON WORKS CO., LTD., 9 mm ⁇ , a flat punch) to provide 250 mg tablets having a tablet hardness of 50 N.
- a rotary tableting machine HT- APl 8SSI I type, HATA IRON WORKS CO., LTD., 9 mm ⁇ , a flat punch
- cilostazol powder 40 parts by weight of cilostazol powder and 0.5 parts by weight of light anhydrous silicic acid (Adsolider-101, Freund Corporation) were mixed. And then, 33.7 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO., LTD.), 15 parts by weight of crystalline cellulose (Ceolus PH-101, Asahi Kasei Chemicals Corporation) , 10 parts by weight of corn starch (Nisshoku corn starch (XXl 6) W, Nihon Shokuhin Kako Co., Ltd.), 0.2 parts by weight of menthol (Takasago International
- Example 7 The resulting mixture was compression-molded with a rotary tableting machine (HT-AP18SSII type, HATA IRON WORKS CO., LTD., 9 mm ⁇ , a flat punch) to provide 250 mg tablets having a tablet hardness of 50 N. [0047] (Example 7)
- cilostazol powder 40 parts by weight of cilostazol powder and 0.5 parts by weight of hydrous silicon dioxide (Adsolider-102, Freund Corporation) were mixed. And then, 33.7 parts by weight of granulated particles (F-MELT, FUJI CHEMICAL INDUSTRY CO. ,LTD.), 10 parts by weight of crystalline cellulose
- 100 mg cilostazol tablets of Examples 1 to 7 and Reference Examples 1 and 2 were put in oral cavity and disintegrated on a tongue.
- the time required for each tablet to be completely disintegrated was measured as an oral disintegration time and compared each other.
- the pharmacopoeia disintegration time and the hardness of Examples 1 to 7 were also measured.
- the hardness was measured with a Monsanto hardness tester (Kayagaki Irika Kougyo) , and the pharmacopoeia disintegration time was measured as time (sec.) required for each tablet to be completely disintegrated, according to the disintegration test in the Japanese pharmacopoeia 15th edition.
- the disintegration test was carried out with water as a test solution and without a disk.
- Example 4 In each process in Examples 1 to 7, especially, the pre-tableted compositions in Examples 4 to 7 which comprise a glidant had a better fluidity than those of Examples 1 to 3 and could be easily compression-molded.
- the feeling test in oral cavity when administered was done. The feeling in oral cavity when administered was good in both the tablets, but the feeling of Example 7 was better than that of Example 4.
- Example 8 40 parts by weight of cilostazol powder and 1.2 parts by weight of light anhydrous silicic acid (Adsolider-101, Freund Corporation) were mixed stirring in a high speed vertical granulator (VG-IO, POWREX CORPORATION, main paddle: 400 rpm, granulating paddle: 1500 rpm) for 15 minutes.
- VG-IO high speed vertical granulator
- XX16 XX16
- Nihon Shokuhin Kako Co., Ltd. granulated particles
- Example 9 40 parts by weight of cilostazol powder and 1.2 parts by weight of light anhydrous silicic acid (Adsolider-101, Freund Corporation) were mixed stirring in a high speed vertical granulator (FM-VG-120P, POWREX CORPORATION, main paddle: 240 rpm, granulating paddle: 1500 rpm) for 15 minutes.
- FM-VG-120P high speed vertical granulator
- the shape of the punch was circular form, the diameter thereof was 9 mm, and the tableting pressure was 400-500 kg.
- the tablets prepared in Examples 8 and 9 were tested about some formulation properties, and the results were shown in Table 2.
- the hardness was measured with a tablet hardness tester (Schleuniger) , and the pharmacopoeia disintegration time was measured as time (sec.) required for each tablet to be completely disintegrated, according to the disintegration test in the Japanese pharmacopoeia 15th edition.
- the disintegration test was carried out with water as a test solution and without a disk.
- the test was carried out with 6 tablets, the report was shown as an average thereof.
- the tablets were orally administered to 6 healthy male adults, and -the time required for each tablet to be completely disintegrated in oral cavity only with saliva was measured. The results were shown below as an average thereof.
- the dissolution test was done according to the dissolution test in the Japanese pharmacopoeia 15th edition, wherein the test solution was 900 ml of aqueous sodium lauryl sulfate (3 g in 1000 mL) , the method was paddle method, and the spinning rate was 50 rpm. The content of each sample was assayed by an ultraviolet-visible spectrophotometry (257 nm) .
- Example 7 The tests were done with 3 tablets of Example 7, 6 tablets of Example 9 and 6 of the commercially available tablets containing 100 mg of cilostazol. The results were shown below as an average thereof.
- the orally disintegrating tablet prepared according to the composition and the process shown in Example 9 had an equivalent dissolution profile with the commercially available tablets containing 100 mg of cilostazol.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008050460 | 2008-02-29 | ||
PCT/JP2009/054115 WO2009107864A2 (en) | 2008-02-29 | 2009-02-26 | An orally disintegrating tablet |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2262487A2 true EP2262487A2 (en) | 2010-12-22 |
Family
ID=40718911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09714454A Withdrawn EP2262487A2 (en) | 2008-02-29 | 2009-02-26 | An orally disintegrating tablet of cilostazol |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2262487A2 (en) |
JP (1) | JP2011513194A (en) |
AR (1) | AR070530A1 (en) |
CL (1) | CL2009000452A1 (en) |
PE (1) | PE20091560A1 (en) |
TW (1) | TW200936184A (en) |
WO (1) | WO2009107864A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3409294A1 (en) | 2017-06-01 | 2018-12-05 | Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. | Tablets containing cilostazol of specific particle size distribution |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011158110A2 (en) | 2010-04-28 | 2011-12-22 | Nuformix Limited | Cilostazol cocrystals and compositions |
ES2422657B1 (en) * | 2012-02-10 | 2014-06-11 | Laboratorios Normon S.A. | Cilostazol solid pharmaceutical composition |
EP2875830A4 (en) | 2012-07-20 | 2016-02-24 | Otsuka Pharma Co Ltd | Tablet having dry-ink film on surface thereof, and ink for inkjet printer |
US20160136091A1 (en) | 2013-07-19 | 2016-05-19 | Sanwa Kagaku Kenkyusho Co., Ltd. | Orally Disintegrating Tablet |
EP3050575B1 (en) * | 2013-09-27 | 2020-05-06 | Daicel Corporation | Disintegrating particle composition produced by two-stage wet granulation process, and intraorally disintegrating tablet containing same composition |
US10231914B2 (en) * | 2015-06-02 | 2019-03-19 | Lynette Batton | Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
AU2001248751A1 (en) * | 2000-04-12 | 2001-10-23 | Banyu Pharmaceutical Co. Ltd. | Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity |
JP4637338B2 (en) * | 2000-09-22 | 2011-02-23 | 大塚製薬株式会社 | Cilostazol dry coated tablets |
JP4551627B2 (en) * | 2003-02-28 | 2010-09-29 | 東和薬品株式会社 | Method for producing orally disintegrating tablets |
JP3841804B2 (en) * | 2003-10-15 | 2006-11-08 | 富士化学工業株式会社 | Composition for intraorally rapidly disintegrating tablets |
EP1674083B1 (en) * | 2003-10-15 | 2018-08-01 | Fuji Chemical Industry Co., Ltd. | Tablet quickly disintegrating in oral cavity |
TWI383809B (en) * | 2005-06-29 | 2013-02-01 | Otsuka Pharma Co Ltd | Orally disintegrating powder comprising cilostazol |
WO2007029376A1 (en) * | 2005-09-02 | 2007-03-15 | Fuji Chemical Industry Co., Ltd. | Orally rapidly disintegrating tablet |
-
2009
- 2009-02-26 JP JP2010504975A patent/JP2011513194A/en active Pending
- 2009-02-26 EP EP09714454A patent/EP2262487A2/en not_active Withdrawn
- 2009-02-26 WO PCT/JP2009/054115 patent/WO2009107864A2/en active Application Filing
- 2009-02-27 CL CL2009000452A patent/CL2009000452A1/en unknown
- 2009-02-27 TW TW098106341A patent/TW200936184A/en unknown
- 2009-02-27 PE PE2009000311A patent/PE20091560A1/en not_active Application Discontinuation
- 2009-02-27 AR ARP090100682A patent/AR070530A1/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2009107864A2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3409294A1 (en) | 2017-06-01 | 2018-12-05 | Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. | Tablets containing cilostazol of specific particle size distribution |
Also Published As
Publication number | Publication date |
---|---|
PE20091560A1 (en) | 2009-10-30 |
TW200936184A (en) | 2009-09-01 |
AR070530A1 (en) | 2010-04-14 |
JP2011513194A (en) | 2011-04-28 |
CL2009000452A1 (en) | 2010-03-26 |
WO2009107864A2 (en) | 2009-09-03 |
WO2009107864A3 (en) | 2009-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3841804B2 (en) | Composition for intraorally rapidly disintegrating tablets | |
TWI376243B (en) | Oral disintegrating tablet | |
JP4551092B2 (en) | Orally rapidly disintegrating tablets | |
JP5074190B2 (en) | Orally rapidly disintegrating tablets | |
JP5296456B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
KR20130030306A (en) | Pharmaceutical compositions | |
JP2009114113A (en) | Intraorally disintegrable tablet and method for producing the same | |
WO2011019043A1 (en) | Tablet that disintegrates rapidly in the mouth and that contains two or more types of particles | |
WO2009107864A2 (en) | An orally disintegrating tablet | |
JP5870690B2 (en) | Orally disintegrating tablet and method for producing the same | |
JP2000212094A (en) | Pharmaceutical preparation for oral cavity | |
JP2017141299A (en) | Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet | |
KR100957731B1 (en) | Pranlukast hydrate-containing preparation having relieved bitterness | |
TWI383809B (en) | Orally disintegrating powder comprising cilostazol | |
JP2010241760A (en) | Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same | |
JP3899522B2 (en) | Formulation containing pranlukast hydrate with reduced bitterness | |
JP5275815B2 (en) | Orally disintegrating tablets and bitterness-suppressing preparations containing risperidone | |
JP5978335B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
JP2005139086A (en) | Quick-disintegration preparation | |
JP6151413B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
JP5714652B2 (en) | Irbesartan-containing pharmaceutical composition with good dissolution and orally disintegrating tablet | |
JP3637968B1 (en) | Gastric disintegrating tablets | |
WO2020209350A1 (en) | Rapid disintegrating oral tablet for treatment of diabetes | |
JP2021113237A (en) | Irbesartan-containing pharmaceutical composition showing excellent elution, and orally disintegrable tablet | |
JP2018168185A (en) | Irbesartan-containing pharmaceutical composition and orally disintegrable tablet with excellent elution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091126 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1148961 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20140625 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150216 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150627 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1148961 Country of ref document: HK |